Literature DB >> 28534530

Haematological cancer: Pembrolizumab is effective in multiple myeloma.

Peter Sidaway.   

Abstract

Entities:  

Year:  2017        PMID： 28534530     DOI： 10.1038/nrclinonc.2017.76

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Authors:  Ashraf Badros; Elizabeth Hyjek; Ning Ma; Alexander Lesokhin; Ahmet Dogan; Aaron P Rapoport; Mehmet Kocoglu; Emily Lederer; Sunita Philip; Todd Milliron; Cameron Dell; Olga Goloubeva; Zeba Singh
Journal:  Blood       Date:  2017-05-01       Impact factor: 22.113
  1 in total
  1 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.